Cleared Traditional

K981913 - PREVUE(TM) BORRELIA BURGDORFERI ANTIBODY DETECTION ASSAY

K981913 is an FDA 510(k) clearance for PREVUE(TM) BORRELIA BURGDORFERI ANTIBOD..., manufactured by Chembio Diagnostic Systems, Inc.. The device is a Class 2 Microbiology device with product code LSR cleared through the Traditional 510(k) pathway after a 256-day FDA review.

K981913 · Chembio Diagnostic Systems, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1999
Decision
256d
Days
Class 2
Risk

K981913 is an FDA 510(k) clearance for the PREVUE(TM) BORRELIA BURGDORFERI ANTIBODY DETECTION ASSAY. Classified as Reagent, Borrelia Serological Reagent (product code LSR), Class II - Special Controls.

Submitted by Chembio Diagnostic Systems, Inc. (Stony Brook, US). The FDA issued a Cleared decision on February 12, 1999 after a review of 256 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3830 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Chembio Diagnostic Systems, Inc. devices

FDA 510(k) Submission Details - K981913

510(k) Number K981913 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 01, 1998
Decision Date February 12, 1999
Days to Decision 256 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
154d slower than avg
Panel avg: 102d · This submission: 256d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LSR Device Classification - Class 2, Special Controls

Product Code LSR Reagent, Borrelia Serological Reagent
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3830
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - LSR Reagent, Borrelia Serological Reagent

All 83
Devices cleared under the same product code (LSR) and FDA review panel - the closest regulatory comparables to K981913.
QUANTA LITE LYME IGM ELISA
K984234 · Inova Diagnostics, Inc. · Apr 1999
APTUS (AUTOMATED) APPLICATION FOR THE B. BURGDORFERI ANTIBODY ELISA TEST SYSTEM
K984138 · Zeus Scientific, Inc. · Mar 1999
BBI-BIOTECH RESEARCH LABORATORIES B. BURGDORFERI IGM WESTERN BLOT KIT
K980351 · Boston Biomedica, Inc. · Mar 1999
IS BORRELIA BURGDORFERI IGG/IGM ELISA TEST SYSTEM
K983605 · Columbia Bioscience, Inc. · Dec 1998
IS BORRELIA BURGDORFERI IGM TEST SYSTEM
K983606 · Columbia Bioscience, Inc. · Dec 1998
LYME DISEASE B. BURGDORFERI GENOGROUP 1 WESTERN BLOT IGG (WB0400G)
K971006 · Mrl Diagnostics · Jun 1998